Pfizer RSV vaccine for older adults is only slightly less effective after 18 months

Pfizer 's vaccine that protects adults ages 60 and older from respiratory syncytial virus was slightly less effective after 18 months, according to clinical trial results the company announced Wednesday. The data is from New York-based Pfizer's clinical trial on more than 34,000 older adults over…

#pfizer #rsv #northernhemisphere #glaxosmithkline #annaliesaanderson #cdc